About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This BlogEye on FDA is published by Mark Senak of FleishmanHillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
My Favorite Dogs
Monthly Archives: September 2012
Using the occasion of the announcement by Twitter that it has rebuilt its i-Pad app “from the ground up” to provide an update to last week’s posting on FDA’s twitter feeds and their influence as measured by Kred. Assessing influence … Continue reading →
Twitter has become an important medium in journalism. It allows reporters to report on much more granular information to a much more targeted audience. Likewise, it allows for any institution or individual or brand to do so as well. While … Continue reading →
On the last day in July just before an August hiatus, I put up a posting called “Blogging, Health and Journalism” where I provided thoughts on different classifications of bloggers in the context of healthcare. And while I think there … Continue reading →